Drug intelligence / Profile preview

Y GUT sensitive

Development stage: Unknown
Lead developer: veMico
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Y GUT sensitive is a postbiotic and prebiotic dietary supplement developed by veMico Ltd. to support gut health and metabolic function. The formulation, often referred to as YMETA in clinical research, consists of 60% galacto-oligosaccharides (GOS), 8% exopolysaccharides (EPS) derived from *Bifidobacterium breve* 091109, and 32% konjac glucomannan (KGM). The GOS component is specifically synthesized using β-galactosidase from the same *Bifidobacterium* strain. Y GUT sensitive is designed to strengthen the intestinal barrier, nourish beneficial gut bacteria, and modulate immune responses. It has been clinically investigated for its efficacy in alleviating digestive discomfort and improving metabolic markers, such as insulin resistance and systemic inflammation, particularly in individuals with prediabetes.

Brand names: Y GUT sensitive
Other names: veMico-gut barrier-immune regulation-GOS-postbioticYMETA formulation

Beyond the preview

Go deeper on Y GUT sensitive.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y GUT sensitive.

Explore the full profile